Paul Tejera, MD
Endocrinology, Diabetes & Metabolism · Canton, NYNPI 1295047736
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,626 of the $45,979 with a category attached, or 75.3%. Novo Nordisk accounts for 74.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $15,068 and has fallen 98.7% since, to $203 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 479 payments — averaging $95.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$34K
- Johnson & Johnson$5K
- Lilly USA, LLC$2K
- Amgen$729
- Abbott$610
- AstraZeneca$596
- plus $3K from 12 others
What the payments were for
- Speaking & faculty fees$34,62675%
- Travel & lodging$2,0094%
- Food & beverage$9,12520%
- Education$1200%
- Other$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 152 | $34,388 |
| Johnson & Johnson | 9 | $5,003 |
| Lilly USA, LLC | 90 | $1,860 |
| Amgen | 36 | $729 |
| Abbott | 22 | $610 |
| AstraZeneca(2 entities) | 27 | $596 |
| Sanofi-aventis U.S. LLC | 29 | $553 |
| Dexcom, Inc. | 25 | $541 |
| Tandem Diabetes Care, Inc. | 18 | $387 |
| Xeris Pharmaceuticals, Inc. | 14 | $286 |
| Boehringer Ingelheim | 16 | $273 |
| Medtronic(2 entities) | 12 | $208 |
| Merck | 11 | $176 |
| Corcept Therapeutics | 6 | $126 |
| Insulet Corporation | 3 | $100 |
| IBSA Pharma Inc. | 5 | $88 |
| AbbVie | 3 | $45 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,979 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 594 | $984,503 |
| MounjaroTirzepatide | 367 | $472,090 |
| TrulicityDulaglutide | 247 | $408,815 |
| Tresiba Flextouch U-200Insulin Degludec | 193 | $376,998 |
| JardianceEmpagliflozin | 260 | $277,050 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 77 | $203,472 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $137,628 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 210 | $125,478 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 79 | $108,386 |
| Novolog FlexpenInsulin Aspart | 260 | $104,230 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 79 | $102,521 |
| Tresiba Flextouch U-100Insulin Degludec | 134 | $95,779 |
| FarxigaDapagliflozin Propanediol | 88 | $93,615 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $89,609 |
| JanuviaSitagliptin Phosphate | 74 | $85,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $34,388 | $1,072,511706 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humalog Mix 75-25 | $1,860 | $900,376653 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $273 | $385,436339 claims |
| MerckJanuvia, Janumet Xr, Janumet | $176 | $167,633137 claims |
| AstraZenecaFarxiga | $596 | $93,61588 claims |
| AmgenProlia | $729 | $39,84523 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $553 | $31,38048 claims |
| Johnson & JohnsonInvokana | $5,003 | $24,84018 claims |
| AbbVieSynthroid | $45 | $9,018152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Canton
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.